Base de dados : MEDLINE
Pesquisa : D04.345.566.075 [Categoria DeCS]
Referências encontradas : 1933 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 194 ir para página                         

  1 / 1933 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29025663
[Au] Autor:Li X; Wang Z; Li Y; Bian K; Yin T; Gao D
[Ad] Endereço:Hebei Key Laboratory of Applied Chemistry, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China.
[Ti] Título:Self-assembly of bacitracin-gold nanoparticles and their toxicity analysis.
[So] Source:Mater Sci Eng C Mater Biol Appl;82:310-316, 2018 Jan 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:As the widely use of gold nanoparticles (AuNPs) in drug delivery, the precise control on the size and morphology of the AuNPs is urgently required. In this scenario, traditional synthesis methods cannot meet current requirement because of their inherent defects. We have depicted here a novel method for fabricating monodispersed large size gold nanoparticles, based on the self-assembly of bacitracin. The AuNPs could be facilely, low-cost, and green synthesized with repeatability and controllability in this method. The Bac gold nanoparticles (Bac-AuNPs), composed by bacitracin core and gold shell, exhibited a spherical morphology in TEM and a face-centered cubic crystal structure in X-Ray diffraction and selected area electron diffraction. The mean diameter of the Bac-AuNPs was 89nm. The nanoparticles were mono-dispersed and the zeta potential of the nanoparticles was 4.1±0.64mV. Notably, in cell viability assay, the Bac-AuNPs showed less toxicity to HepG2 cells and HEK293 cells compared to small size AuNPs. Collectively, the size, rheological characteristic and the biocompatibility supported the use of the gold nanoparticles as intracellular delivery vehicles for drug delivery, especially for tumor therapy. And this study could provide a maneuverable, controllable and green strategy for the synthesis of AuNPs, which would be applied in disease diagnosis and therapy with biosafety.
[Mh] Termos MeSH primário: Bacitracina/química
Ouro/química
Nanopartículas Metálicas/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/química
Materiais Biocompatíveis/toxicidade
Sobrevivência Celular/efeitos dos fármacos
Química Verde
Células HEK293
Células Hep G2
Seres Humanos
Concentração de Íons de Hidrogênio
Nanopartículas Metálicas/toxicidade
Oxirredução
Tamanho da Partícula
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 1405-87-4 (Bacitracin); 7440-57-5 (Gold)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171014
[St] Status:MEDLINE


  2 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28790058
[Au] Autor:Colantonio S; Kirshen C
[Ad] Endereço:Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Ont.
[Ti] Título:Severe allergic contact dermatitis due to Polysporin.
[So] Source:CMAJ;189(31):E1018, 2017 08 08.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Bacitracina/efeitos adversos
Dermatite Alérgica de Contato/etiologia
Gramicidina/efeitos adversos
Polimixina B/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Dermatite Alérgica de Contato/diagnóstico
Combinação de Medicamentos
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (polysporin ointment); 1404-26-8 (Polymyxin B); 1405-87-4 (Bacitracin); 1405-97-6 (Gramicidin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.161214


  3 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28721045
[Au] Autor:Hong W; Gao X; Qiu P; Yang J; Qiao M; Shi H; Zhang D; Tian C; Niu S; Liu M
[Ad] Endereço:Key Laboratory of Zoonosis of Liaoning Province, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenhe, Shenyang, Liaoning, People's Republic of China.
[Ti] Título:Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo.
[So] Source:Int J Nanomedicine;12:4691-4708, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Bacitracin A (BA) is an excellent polypeptide antibiotic that is active against gram-positive bacteria without triggering multidrug resistance. However, BA is inactive against gram-negative bacteria because of its inability to cross the outer membrane of these cells, and it has strong nephrotoxicity, thus limiting its clinical applications. Nanoantibiotics can effectively localize antibiotics to the periplasmic space of bacteria while decreasing the adverse effects of antibiotics. In this study, biodegradable hydrophobic copolymers of poly (d,l-lactide-co-glycolide) (PLGA) were attached to the N-termini of BA to design a novel class of self-assembled nano-bacitracin A (nano-BAs), and their potential as antibacterial agents was evaluated in vitro and in vivo. Nano-BAs had a core-shell structure with a mean diameter <150 nm. Impressively, nano-BAs had strong antibacterial properties against both gram-positive and gram-negative bacteria, and the distribution of antibacterial activity as a function of PLGA block length was skewed toward longer PLGA chains. No cytotoxicity against HK-2 cells or human red blood cells (hRBCs) was observed in vitro, suggesting good biocompatibility. A high local density of BA mass on the surface promoted endocytotic cellular uptake, and hydrophobic interactions between the PLGA block and lipopolysaccharide (LPS) facilitated the uptake of nano-BAs, thereby leading to greater antibacterial activities. In addition, Nano-BA was found to be effective in vivo, and it served as an anti-infective agent for wound healing. Collectively, this study provides a cost-effective means of developing self-assembling nano-polypeptide antibiotic candidates with a broader antibacterial spectrum and a lower toxicity than commercially available peptide antibiotics, owing to their modification with biodegradable copolymers.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bacitracina/síntese química
Bacitracina/farmacologia
Nanopartículas/química
[Mh] Termos MeSH secundário: Animais
Antibacterianos/química
Portadores de Fármacos/síntese química
Portadores de Fármacos/química
Portadores de Fármacos/farmacologia
Eritrócitos/efeitos dos fármacos
Feminino
Bactérias Gram-Negativas/efeitos dos fármacos
Bactérias Gram-Positivas/efeitos dos fármacos
Seres Humanos
Interações Hidrofóbicas e Hidrofílicas
Ácido Láctico/química
Espectroscopia de Ressonância Magnética
Masculino
Camundongos
Testes de Sensibilidade Microbiana
Microscopia Eletrônica de Varredura
Ácido Poliglicólico/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Drug Carriers); 0 (polylactic acid-polyglycolic acid copolymer); 1405-87-4 (Bacitracin); 26009-03-0 (Polyglycolic Acid); 33X04XA5AT (Lactic Acid); DDA3RRX0P7 (bacitracin A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S136998


  4 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28709667
[Au] Autor:Chan JL; Diaconescu AC; Horvath KA
[Ad] Endereço:Cardiothoracic Surgery Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
[Ti] Título:Routine Use of Topical Bacitracin to Prevent Sternal Wound Infections After Cardiac Surgery.
[So] Source:Ann Thorac Surg;104(5):1496-1500, 2017 Nov.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The development of sternal wound infections remains a serious complication after cardiac surgery. A number of studies have assessed the use of topical antibiotics placed on the sternal edges. We evaluated the routine use of bacitracin ointment applied over the sternotomy skin incision as a prophylactic measure against sternal wound infections. METHODS: A retrospective review of all coronary artery bypass graft and valve surgery cases performed at a single institution between 2006 and 2015 was performed (n = 1,495). Appropriate preoperative intravenous antibiotics were administered for all patients. Bacitracin topical antibiotic ointment was routinely applied to the sternal surgical incision after skin closure for all patients during this period. The incidence of sternal wound infection was assessed. RESULTS: During this 9-year experience, no episodes of deep sternal wound infections were observed, compared with a predicted rate of 0.29% (interquartile range: 0.19% to 0.46%) based on The Society of Thoracic Surgeons National Database risk calculator. Four episodes of superficial sternal wound infections were noted; gram-positive organisms were cultured in the majority of these cases. Bacitracin ointment was well tolerated by patients, with no serious adverse effects reported. CONCLUSIONS: This study suggests that the routine application of topical bacitracin over the surgical skin incision is safe after cardiac surgery. Deep sternal wound infections were notably absent during this period. As a readily available and inexpensive therapy, this simple intervention may be a useful adjunct strategy in preventing sternal wound infections.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Bacitracina/uso terapêutico
Ponte de Artéria Coronária/efeitos adversos
Implante de Prótese de Valva Cardíaca/efeitos adversos
Esternotomia/efeitos adversos
Infecção da Ferida Cirúrgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Estudos de Coortes
Ponte de Artéria Coronária/métodos
Feminino
Seguimentos
Implante de Prótese de Valva Cardíaca/métodos
Seres Humanos
Masculino
Meia-Idade
Pomadas/uso terapêutico
Estudos Retrospectivos
Medição de Risco
Esternotomia/métodos
Infecção da Ferida Cirúrgica/prevenção & controle
Resultado do Tratamento
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Ointments); 1405-87-4 (Bacitracin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170716
[St] Status:MEDLINE


  5 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28699496
[Au] Autor:Sharma CK; Sharma M
[Ad] Endereço:Department of Bioscience and Biotechnology, Faculty of Science and Technology, Banasthali University, Rajasthan 304022. India.
[Ti] Título:Up Scaling Strategies to Improve the Industrial Production of Bacitracin at Largescale.
[So] Source:Mini Rev Med Chem;17(16):1548-1556, 2017.
[Is] ISSN:1875-5607
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Bacitracin was discovered and named after a 7 year old American girl, Margaret Tracey in 1943 as Bacillus was isolated from her wounds. Bacillus licheniformis is usually present in soil and bird feathers. This bacterium is most commonly present around back plumage and chest of birds. There are different types of bacitracin but the one most potent is Bacitracin A. Bacitracin induced proteins are localized in bacterial membrane. Production of antibiotic initially stopped, resumed by induction of bacitracin induced protein but after few mitotic divisions microbes reverted to their vulnerable state. Induction of protein ceases after 4th hour of stationary phase. Immobilization is necessary for economic, process convenience and stability of the cell. Moreover, immobilization increases the ability of the cell to produce product in high quantity. CONCLUSION: Maximum production of antibiotic was noted at pH 8 after 4 hours of incubation at various glucose concentrations in shake flask fermentation at 30°C when immobilized in polyacrylamide gel. Increase in antibiotic activity was also found with increase in use of cells. Efforts have been made to alter heterocyclic metal binding subunit of bacitracin by synthesizing heterocyclic building blocks that can be coupled to linear decapeptide and consequently cyclization by PCPTE biodomain of bacitracin. Derivatives of bacitracin showed antimicrobial activities indicating the possibility of overcoming existing limitations just by altering their heterocyclic subunit. Bioactivity and stability can be increased by modifying peptide backbone of compounds.
[Mh] Termos MeSH primário: Antibacterianos/metabolismo
Bacillus licheniformis/metabolismo
Bacitracina/metabolismo
Engenharia Genética/métodos
Microbiologia Industrial/métodos
[Mh] Termos MeSH secundário: Antibacterianos/química
Bacillus licheniformis/genética
Bacillus licheniformis/crescimento & desenvolvimento
Bacitracina/química
Genes Bacterianos
Mutagênese
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 1405-87-4 (Bacitracin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.2174/1389557517666170711165914


  6 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28493903
[Au] Autor:Choi YH; Cho SS; Simkhada JR; Rahman MS; Choi YS; Kim CS; Yoo JC
[Ad] Endereço:Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, Korea.
[Ti] Título:A novel multifunctional peptide oligomer of bacitracin with possible bioindustrial and therapeutic applications from a Korean food-source Bacillus strain.
[So] Source:PLoS One;12(5):e0176971, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONCLUSION: CSP32 has stable characteristics and may find bio-industrial and therapeutic applications.
[Mh] Termos MeSH primário: Antibacterianos/química
Antibacterianos/farmacologia
Anti-Inflamatórios/química
Anti-Inflamatórios/farmacologia
Bacillus/química
Bacitracina/análogos & derivados
Bacitracina/farmacologia
[Mh] Termos MeSH secundário: Animais
Clostridium difficile/efeitos dos fármacos
Citocinas/imunologia
Enterocolite Pseudomembranosa/tratamento farmacológico
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Seres Humanos
Macrófagos/efeitos dos fármacos
Macrófagos/imunologia
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Camundongos
Propionibacterium acnes/efeitos dos fármacos
Células RAW 264.7
Infecções Estafilocócicas/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0 (Cytokines); 1405-87-4 (Bacitracin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176971


  7 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28257555
[Au] Autor:Nelson RL; Suda KJ; Evans CT
[Ad] Endereço:Epidemiology/Biometry Division, University of Illinois School of Public Health, 1603 West Taylor, Room 956, Chicago, Illinois, USA, 60612.
[Ti] Título:Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
[So] Source:Cochrane Database Syst Rev;3:CD004610, 2017 03 03.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhoea and colitis. This review is an update of a previously published Cochrane review. OBJECTIVES: The aim of this review is to investigate the efficacy and safety of antibiotic therapy for C. difficile-associated diarrhoea (CDAD), or C. difficile infection (CDI), being synonymous terms. SEARCH METHODS: We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017. We also searched clinicaltrials.gov and clinicaltrialsregister.eu for ongoing trials. SELECTION CRITERIA: Only randomised controlled trials assessing antibiotic treatment for CDI were included in the review. DATA COLLECTION AND ANALYSIS: Three authors independently assessed abstracts and full text articles for inclusion and extracted data. The risk of bias was independently rated by two authors. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We pooled data using a fixed-effect model, except where significant heterogeneity was detected, at which time a random-effects model was used. The following outcomes were sought: sustained symptomatic cure (defined as initial symptomatic response and no recurrence of CDI), sustained bacteriologic cure, adverse reactions to the intervention, death and cost. MAIN RESULTS: Twenty-two studies (3215 participants) were included. The majority of studies enrolled patients with mild to moderate CDI who could tolerate oral antibiotics. Sixteen of the included studies excluded patients with severe CDI and few patients with severe CDI were included in the other six studies. Twelve different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin, bacitracin, cadazolid, LFF517, surotomycin and fidaxomicin. Most of the studies were active comparator studies comparing vancomycin with other antibiotics. One small study compared vancomycin to placebo. There were no other studies that compared antibiotic treatment to a placebo or a 'no treatment' control group. The risk of bias was rated as high for 17 of 22 included studies. Vancomycin was found to be more effective than metronidazole for achieving symptomatic cure. Seventy-two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; moderate quality evidence). Fidaxomicin was found to be more effective than vancomycin for achieving symptomatic cure. Seventy-one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 95% CI 1.04 to 1.31; moderate quality evidence). Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure. Eightly-seven per cent (48/55) of teicoplanin patients achieved symptomatic cure compared to 73% (40/55) of vancomycin patients (RR 1.21, 95% CI 1.00 to 1.46; very low quality evidence). For other comparisons including the one placebo-controlled study the quality of evidence was low or very low due to imprecision and in many cases high risk of bias because of attrition and lack of blinding. One hundred and forty deaths were reported in the studies, all of which were attributed by study authors to the co-morbidities of the participants that lead to acquiring CDI. Although many other adverse events were reported during therapy, these were attributed to the participants' co-morbidities. The only adverse events directly attributed to study medication were rare nausea and transient elevation of liver enzymes. Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13 (Health Warehouse). Vancomycin 125 mg costs USD 1779 (Walgreens for 56 tablets) compared to fidaxomicin 200 mg at USD 3453.83 or more (Optimer Pharmaceuticals) and teicoplanin at approximately USD 83.67 (GBP 71.40, British National Formulary). AUTHORS' CONCLUSIONS: No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic. Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other two antibiotics. The quality of evidence for teicoplanin is very low. Adequately powered studies are needed to determine if teicoplanin performs as well as the other antibiotics. A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin, would be of interest.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Clostridium difficile
Diarreia/tratamento farmacológico
Enterocolite Pseudomembranosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Aminoglicosídeos/uso terapêutico
Antibacterianos/efeitos adversos
Bacitracina/uso terapêutico
Diarreia/induzido quimicamente
Diarreia/microbiologia
Enterocolite Pseudomembranosa/complicações
Seres Humanos
Metronidazol/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Teicoplanina/uso terapêutico
Resultado do Tratamento
Vancomicina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); 1405-87-4 (Bacitracin); 140QMO216E (Metronidazole); 61036-62-2 (Teicoplanin); 6Q205EH1VU (Vancomycin); Z5N076G8YQ (lipiarmycin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004610.pub5


  8 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28222110
[Au] Autor:Costa MC; Bessegatto JA; Alfieri AA; Weese JS; Filho JA; Oba A
[Ad] Endereço:Department of Veterinary Preventive Medicine, Universidade Estadual de Londrina, Londrina, Paraná, Brazil.
[Ti] Título:Different antibiotic growth promoters induce specific changes in the cecal microbiota membership of broiler chicken.
[So] Source:PLoS One;12(2):e0171642, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antimicrobials are sometimes given to food animals at low doses in order to promote faster growth. However, the mechanisms by which those drugs improve performance are not fully understood. This study aimed to investigate the impact of zinc bacitracin (55g/ton), enramycin (10g/ton); halquinol® (30g/ton); virginiamycin (16,5g/ton) and avilamycin (10g/ton) on the cecal microbiota of broiler chicken, compared to a control group. Six hundred and twenty four chicks (Cobb 500) arriving to an experimental unit were randomly assigned into each treatment with four repetitions per treatment. The cecal content of 16 animals per treatment (n = 96) was used for DNA extraction and sequencing of the V4 region of the 16S rRNA gene using Illumina technology. The use of antimicrobials induced significant changes in membership but not in structure of the cecal microbiota compared to the control group, suggesting a greater impact on the less abundant species of bacteria present in that environment. Halquinol was the only drug that did not affect microbial membership. Firmicutes comprised the major bacterial phylum present in the cecum of all groups. There was no statistical difference in relative abundances of the main phyla between treated animals and the control group (all P>0.05). Treatment with enramycin was associated with decreased richness and with lower relative abundance of unclassified Firmicutes, Clostridium XI, unclassified Peptostreptococcaceae (all P<0.001) and greater abundance of Clostridium XIVb (P = 0.004) and Anaerosporobacter spp. (P = 0.015), and treatment with bacitracin with greater relative abundance of Bilophila spp. (P = 0.004). Several bacterial genera were identified as representative of usage of each drug. This study used high throughput sequencing to characterize the impact of several antimicrobials in broiler chicken under controlled conditions and add new insights to the current knowledge on how AGPs affect the cecal microbiota of chicken.
[Mh] Termos MeSH primário: Ração Animal
Antibacterianos/farmacologia
Ceco/microbiologia
Galinhas/microbiologia
Aditivos Alimentares/farmacologia
Microbioma Gastrointestinal/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antibacterianos/administração & dosagem
Bacitracina/farmacologia
Bactérias/classificação
Bactérias/efeitos dos fármacos
Galinhas/crescimento & desenvolvimento
Cloroquinolinóis/farmacologia
Variação Genética
Oligossacarídeos/farmacologia
Peptídeos/farmacologia
Análise de Componente Principal
Distribuição Aleatória
Ribotipagem
Virginiamicina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Chloroquinolinols); 0 (Food Additives); 0 (Oligosaccharides); 0 (Peptides); 11006-76-1 (Virginiamycin); 1405-87-4 (Bacitracin); 4GP7CLG9EG (enramycin); 720WDX56D3 (avilamycin); Z7Z4BX535U (halquinol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171642


  9 / 1933 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27997719
[Au] Autor:Fang C; Nagy-Staron A; Grafe M; Heermann R; Jung K; Gebhard S; Mascher T
[Ad] Endereço:Department Biology I, Ludwig-Maximilians-Universität München, Großhaderner Str. 2-4, Martinsried, 82152, Germany.
[Ti] Título:Insulation and wiring specificity of BceR-like response regulators and their target promoters in Bacillus subtilis.
[So] Source:Mol Microbiol;104(1):16-31, 2017 04.
[Is] ISSN:1365-2958
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BceRS and PsdRS are paralogous two-component systems in Bacillus subtilis controlling the response to antimicrobial peptides. In the presence of extracellular bacitracin and nisin, respectively, the two response regulators (RRs) bind their target promoters, P or P , resulting in a strong up-regulation of target gene expression and ultimately antibiotic resistance. Despite high sequence similarity between the RRs BceR and PsdR and their known binding sites, no cross-regulation has been observed between them. We therefore investigated the specificity determinants of P and P that ensure the insulation of these two paralogous pathways at the RR-promoter interface. In vivo and in vitro analyses demonstrate that the regulatory regions within these two promoters contain three important elements: in addition to the known (main) binding site, we identified a linker region and a secondary binding site that are crucial for functionality. Initial binding to the high-affinity, low-specificity main binding site is a prerequisite for the subsequent highly specific binding of a second RR dimer to the low-affinity secondary binding site. In addition to this hierarchical cooperative binding, discrimination requires a competition of the two RRs for their respective binding site mediated by only slight differences in binding affinities.
[Mh] Termos MeSH primário: Bacillus subtilis/metabolismo
[Mh] Termos MeSH secundário: Transportadores de Cassetes de Ligação de ATP/metabolismo
Antibacterianos/farmacologia
Bacillus subtilis/genética
Bacitracina/metabolismo
Proteínas de Bactérias/metabolismo
Sequência de Bases
Sítios de Ligação
Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos
Dados de Sequência Molecular
Nisina/metabolismo
Regiões Promotoras Genéticas
Ligação Proteica/genética
Sequências Reguladoras de Ácido Nucleico
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 1405-87-4 (Bacitracin); 1414-45-5 (Nisin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161221
[St] Status:MEDLINE
[do] DOI:10.1111/mmi.13597


  10 / 1933 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27914255
[Au] Autor:Nie B; Ao H; Long T; Zhou J; Tang T; Yue B
[Ad] Endereço:Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, PR China.
[Ti] Título:Immobilizing bacitracin on titanium for prophylaxis of infections and for improving osteoinductivity: An in vivo study.
[So] Source:Colloids Surf B Biointerfaces;150:183-191, 2017 Feb 01.
[Is] ISSN:1873-4367
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Bacitracin immobilized on the titanium (Ti) surface significantly improves anti-bacterial activity and biocompatibility in vitro. In the current study, we investigated the biologic performance (bactericidal effect and bone-implant integration) of bacitracin-modified Ti in vivo. A rat osteomyelitis model with femoral medullary cavity placement of Ti rods was employed to analyze the prophylactic effect of bacitracin-modified Ti (Ti-BC). Thirty-six female Sprague Dawley (SD) rats were used to establish the Ti implant-associated infection. The Ti and Ti-BC rods were incubated with and without Staphylococcus aureus to mimic the contaminated Ti rod and were implanted into the medullary cavity of the left femur, and sterile Ti rods were used as the blank control. After 3 weeks, the bone pathology was evaluated using X-ray and micro-computed tomography (micro-CT) analysis. For the investigation of the Ti-BC implant osseointegration in vivo, fifteen SD rats were divided into three groups (N=5), namely Ti, Ti-dopamine immobilized (Ti-DOPA), and Ti-BC. Ti rods were implanted into the left femoral cavity and micro-CT and histological evaluation was conducted after 12 weeks. The in vivo study indicated that Ti-immobilized bacitracin owned the prophylaxis potential for the infection associated with the Ti implants and allowed for the osseointegration. Thus, the multiple biofunctionalized Ti implants could be realized via immobilization of bacitracin, making them promising candidates for preventing the Ti implant-associated infections while retaining the osseointegration effects.
[Mh] Termos MeSH primário: Bacitracina/química
Proteínas Imobilizadas/química
Osseointegração/fisiologia
Osteomielite/tratamento farmacológico
Titânio/química
[Mh] Termos MeSH secundário: Animais
Antibacterianos/química
Substitutos Ósseos
Osso e Ossos/metabolismo
Materiais Revestidos Biocompatíveis/farmacologia
Implantes Dentários
Feminino
Fêmur/cirurgia
Ratos
Ratos Sprague-Dawley
Staphylococcus aureus
Propriedades de Superfície
Microtomografia por Raio-X
Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bone Substitutes); 0 (Coated Materials, Biocompatible); 0 (Dental Implants); 0 (Immobilized Proteins); 1405-87-4 (Bacitracin); D1JT611TNE (Titanium)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170328
[Lr] Data última revisão:
170328
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE



página 1 de 194 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde